Glenmark Pharmaceuticals (NSE:GLENMARK) EV-to-Revenue : 2.54 (As of May. 05, 2024)

View and export this data going back to 2000. Start your Free Trial

What is Glenmark Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Glenmark Pharmaceuticals's enterprise value is ₹335,744 Mil. Glenmark Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₹132,090 Mil. Therefore, Glenmark Pharmaceuticals's EV-to-Revenue for today is 2.54.

The historical rank and industry rank for Glenmark Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

NSE:GLENMARK' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.55 Med: 1.98 Max: 5.02
Current: 2.54

During the past 13 years, the highest EV-to-Revenue of Glenmark Pharmaceuticals was 5.02. The lowest was 0.55. And the median was 1.98.

NSE:GLENMARK's EV-to-Revenue is ranked worse than
52.93% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 2.36 vs NSE:GLENMARK: 2.54

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-05), Glenmark Pharmaceuticals's stock price is ₹1053.30. Glenmark Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₹467.92. Therefore, Glenmark Pharmaceuticals's PS Ratio for today is 2.25.

Glenmark Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Glenmark Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glenmark Pharmaceuticals EV-to-Revenue Chart

Glenmark Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EV-to-Revenue

Get a 7-Day Free Trial

2.22

0.94

1.56

1.26

1.31

Glenmark Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															1.02	1.31	1.40	2.05	1.82

Competitive Comparison of Glenmark Pharmaceuticals's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Glenmark Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Glenmark Pharmaceuticals's EV-to-Revenue falls into.

Glenmark Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Glenmark Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	335743.696	/	132089.84
	=	2.54

Glenmark Pharmaceuticals's current Enterprise Value is ₹335,744 Mil.
Glenmark Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹132,090 Mil.

Glenmark Pharmaceuticals (NSE:GLENMARK) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Glenmark Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1053.30	/	467.923
	=	2.25

Glenmark Pharmaceuticals's share price for today is ₹1053.30.
Glenmark Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹467.92.

Glenmark Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Glenmark Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Glenmark Pharmaceuticals (NSE:GLENMARK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Pharmaceuticals Ltd (NSE:GLENMARK) » Definitions » EV-to-Revenue

Traded in Other Exchanges

532296:India

Address

Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai, IND, 400099

Website

https://www.glenmarkpharma.com

Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities.

Glenmark Pharmaceuticals (NSE:GLENMARK) Headlines

No Headlines